TY  - JOUR
AU  - Baraliakos, Xenofon
AU  - Witte, Torsten
AU  - De Clerck, Luc
AU  - Frediani, Bruno
AU  - Collantes-Estevez, Eduardo
AU  - Katsifis, Gkikas
AU  - VanLunen, Brenda
AU  - Kleine, Elisabeth
AU  - Hoepken, Bengt
AU  - Bauer, Lars
AU  - Goodson, Nicola
PY  - 2020
DO  - 10.1093/rheumatology/keaa181
UR  - http://hdl.handle.net/10668/15824
T2  - Rheumatology (Oxford, England)
AB  - The efficacy and safety of certolizumab pegol (CZP), an Fc-free, PEGylated anti-TNF, in axial spondyloarthritis (axSpA) has been established in clinical trial settings. We report CZP effectiveness and safety in European clinical practice in patients...
LA  - en
PB  - Oxford University Press
KW  - Axial spondyloarthritis
KW  - Certolizumab pegol
KW  - Non-interventional
KW  - Adult
KW  - Aged
KW  - Antirheumatic agents
KW  - Certolizumab pegol
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle aged
KW  - Prospective studies
KW  - Severity of illness index
KW  - Spondylarthritis
KW  - Young adult
TI  - Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
TY  - research article
VL  - 60
ER  -